학술논문

History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium
Document Type
article
Source
Cancer Causes & Control. 28(5)
Subject
Epidemiology
Biomedical and Clinical Sciences
Health Sciences
Oncology and Carcinogenesis
Clinical Research
Cancer
Diabetes
Ovarian Cancer
Rare Diseases
Genetics
Cardiovascular
Detection
screening and diagnosis
4.1 Discovery and preclinical testing of markers and technologies
Good Health and Well Being
Adrenergic beta-Antagonists
Adult
Aged
Diabetes Mellitus
Disease-Free Survival
Female
Heart Diseases
Humans
Hypertension
Hypoglycemic Agents
Insulin
Middle Aged
Ovarian Neoplasms
Risk
Survival Rate
Ovarian cancer prognosis
Medications
Mortality
Beta blockers
Australian Ovarian Cancer Study Group
Ovarian Cancer Association Consortium
Public Health and Health Services
Oncology and carcinogenesis
Language
Abstract
PurposeSurvival following ovarian cancer diagnosis is generally low; understanding factors related to prognosis could be important to optimize treatment. The role of previously diagnosed comorbidities and use of medications for those conditions in relation to prognosis for ovarian cancer patients has not been studied extensively, particularly according to histological subtype.MethodsUsing pooled data from fifteen studies participating in the Ovarian Cancer Association Consortium, we examined the associations between history of hypertension, heart disease, diabetes, and medications taken for these conditions and overall survival (OS) and progression-free survival (PFS) among patients diagnosed with invasive epithelial ovarian carcinoma. We used Cox proportional hazards regression models adjusted for age and stage to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) overall and within strata of histological subtypes.ResultsHistory of diabetes was associated with increased risk of mortality (n = 7,674; HR = 1.12; 95% CI = 1.01-1.25). No significant mortality associations were observed for hypertension (n = 6,482; HR = 0.95; 95% CI = 0.88-1.02) or heart disease (n = 4,252; HR = 1.05; 95% CI = 0.87-1.27). No association of these comorbidities was found with PFS in the overall study population. However, among patients with endometrioid tumors, hypertension was associated with lower risk of progression (n = 339, HR = 0.54; 95% CI = 0.35-0.84). Comorbidity was not associated with OS or PFS for any of the other histological subtypes. Ever use of beta blockers, oral antidiabetic medications, and insulin was associated with increased mortality, HR = 1.20; 95% CI = 1.03-1.40, HR = 1.28; 95% CI = 1.05-1.55, and HR = 1.63; 95% CI = 1.20-2.20, respectively. Ever use of diuretics was inversely associated with mortality, HR = 0.71; 95% CI = 0.53-0.94.ConclusionsHistories of hypertension, diabetes, and use of diuretics, beta blockers, insulin, and oral antidiabetic medications may influence the survival of ovarian cancer patients. Understanding mechanisms for these observations could provide insight regarding treatment.